Jubilant Ingrevia announced on June 27 that its Unit-1 manufacturing facility in Bharuch, Gujarat, received an establishment inspection report (EIR) from the USFDA with no observations.
Deepak Jain, CEO & Managing Director of Jubilant Ingrevia, said, “We are happy to announce that our Bharuch Unit-1, which produces Nutraceuticals and Dietary Active Ingredients, passed its first USFDA inspection with no issues. This shows our commitment to high-quality and compliance standards. It also highlights our team’s dedication and ability to deliver safe, effective, and high-quality products.”
The FDA officials conducted the inspection in April to check compliance with Good Manufacturing Practices (GMP) and other regulations for products intended for human use.
Jubilant Ingrevia noted that this GMP-compliant facility in Bharuch, part of the company’s expansion plan, will help them enter regulated markets and meet the growing demands in Nutraceuticals, Dietary Active Ingredients, Cosmetic Grade Applications, Drug Intermediates, and CDMO products.
Jubilant Ingrevia also stated that Unit-1, already GMP compliant and undergoing expansion as part of strategic capital expenditure, will boost its ability to serve regulated markets. The facility aims to support growth in Nutraceuticals, Dietary Active Ingredients, Cosmetic Grade Applications, Drug Intermediates, and Custom Development & Manufacturing (CDMO) products for various industrial applications and human consumption.
Jubilant Ingrevia is a global provider of integrated life science products and innovative solutions, serving the Pharmaceutical, Nutrition, Agrochemical, Consumer, and Industrial sectors. They focus on delivering customized, high-quality products that meet strict regulatory standards. According to the Bombay Stock Exchange (BSE), the market capitalization of Jubilant Ingrevia is Rs 8,383.76 crore.
